Clontech renegotiates Becton sale:
This article was originally published in Clinica
Clontech Laboratories, a privately-owned US molecular biology and gene-based drug discovery company, has renegotiated its April agreement to sell to Becton Dickinson. The revised agreement has Becton paying the $200 million purchase price in cash, rather than in Becton shares as was originally agreed.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.